BioCentury | Jan 27, 2021
Finance

Pontifax’s largest-ever fund, at $404M, will help firm maintain stakes in growth-stage portfolio companies

Building on a string of successful exits with its sixth and largest fund, Pontifax Venture Capital will now have a larger reserve of capital to maintain its ownership stakes in portfolio companies into the growth...
BioCentury | Dec 31, 2020
Product Development

Stoffels on how J&J designed its COVID-19 vaccine for maximum impact: a BioCentury audio interview

Johnson & Johnson’s COVID-19 vaccine won’t be the first to reach the market, but it could be one of the most important. The company has made scientific and business decisions about the vaccine’s profile that,...
BioCentury | Feb 13, 2020
Product Development

COVID-19 update: Remdesivir readout in weeks; hospital-use diagnostic under development; antibodies advancing

...said in a statement. In parallel, Janssen Pharmaceuticals, a unit of J&J, “will work to upscale...
BioCentury | Jul 11, 2016
Company News

Mologen cancer, infectious news

Mologen will reduce headcount by 17 (26%) to 49 and focus on developing lead product lefitolimod ( MGN1703 ), a toll-like receptor 9 (TLR9) agonist based on double Stem Loop Immunomodulator (dSLIM) technology. The company will...
BioCentury | Jan 22, 2015
Distillery Techniques

Techniques: Cartilagenous extracellular matrix (ECM) templates

Drug platforms TECHNOLOGY: Cell therapy Implantable cartilagenous ECM templates could be used to promote bone repair and treat diseases associated with bone loss. The ECM templates were generated by differentiating primary human mesenchymal stem cells...
BioCentury | Nov 3, 2014
Emerging Company Profile

SutroVax: Upscaled antigens

SutroVax Inc. spun out of Sutro Biopharma Inc. to capitalize on the scalability of Sutro's Xpress CF cell-free protein synthesis platform in the production of vaccine antigens. Comparable technologies produce protein only in minute amounts,...
BioCentury | Dec 5, 2013
Distillery Techniques

Technology: Drug platforms

Approach Summary Licensing status Publication and contact information Drug platforms Expandable and transplantable fetal intestinal progenitors with colon-regenerative potential Intestinal progenitor cells with fetal characteristics could be used to repair injured colon epithelium. Ex vivo,...
BioCentury | Dec 20, 2012
Cover Story

Translating mRNA vaccines

...these approaches have multiple limitations, including a risk of contamination and an inability to rapidly upscale...
BioCentury | Dec 4, 1995
Company News

BioSepra, Sepragen sales and marketing update

...SPGNU will sell BSEP's line of Upscale Process Chromatography Columns in the U.S. on a semi-exclusive...
BioCentury | Aug 9, 1993
Strategy

How DNAP tested its tomatoes

...15.8 percent, three times what the company expected. The target market for the tomatoes is upscale...
Items per page:
1 - 10 of 10
BioCentury | Jan 27, 2021
Finance

Pontifax’s largest-ever fund, at $404M, will help firm maintain stakes in growth-stage portfolio companies

Building on a string of successful exits with its sixth and largest fund, Pontifax Venture Capital will now have a larger reserve of capital to maintain its ownership stakes in portfolio companies into the growth...
BioCentury | Dec 31, 2020
Product Development

Stoffels on how J&J designed its COVID-19 vaccine for maximum impact: a BioCentury audio interview

Johnson & Johnson’s COVID-19 vaccine won’t be the first to reach the market, but it could be one of the most important. The company has made scientific and business decisions about the vaccine’s profile that,...
BioCentury | Feb 13, 2020
Product Development

COVID-19 update: Remdesivir readout in weeks; hospital-use diagnostic under development; antibodies advancing

...said in a statement. In parallel, Janssen Pharmaceuticals, a unit of J&J, “will work to upscale...
BioCentury | Jul 11, 2016
Company News

Mologen cancer, infectious news

Mologen will reduce headcount by 17 (26%) to 49 and focus on developing lead product lefitolimod ( MGN1703 ), a toll-like receptor 9 (TLR9) agonist based on double Stem Loop Immunomodulator (dSLIM) technology. The company will...
BioCentury | Jan 22, 2015
Distillery Techniques

Techniques: Cartilagenous extracellular matrix (ECM) templates

Drug platforms TECHNOLOGY: Cell therapy Implantable cartilagenous ECM templates could be used to promote bone repair and treat diseases associated with bone loss. The ECM templates were generated by differentiating primary human mesenchymal stem cells...
BioCentury | Nov 3, 2014
Emerging Company Profile

SutroVax: Upscaled antigens

SutroVax Inc. spun out of Sutro Biopharma Inc. to capitalize on the scalability of Sutro's Xpress CF cell-free protein synthesis platform in the production of vaccine antigens. Comparable technologies produce protein only in minute amounts,...
BioCentury | Dec 5, 2013
Distillery Techniques

Technology: Drug platforms

Approach Summary Licensing status Publication and contact information Drug platforms Expandable and transplantable fetal intestinal progenitors with colon-regenerative potential Intestinal progenitor cells with fetal characteristics could be used to repair injured colon epithelium. Ex vivo,...
BioCentury | Dec 20, 2012
Cover Story

Translating mRNA vaccines

...these approaches have multiple limitations, including a risk of contamination and an inability to rapidly upscale...
BioCentury | Dec 4, 1995
Company News

BioSepra, Sepragen sales and marketing update

...SPGNU will sell BSEP's line of Upscale Process Chromatography Columns in the U.S. on a semi-exclusive...
BioCentury | Aug 9, 1993
Strategy

How DNAP tested its tomatoes

...15.8 percent, three times what the company expected. The target market for the tomatoes is upscale...
Items per page:
1 - 10 of 10